We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+10.75%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3B
AUM Growth
-$85.7M
Cap. Flow
-$518M
Cap. Flow %
-17.24%
Top 10 Hldgs %
35.54%
Holding
152
New
30
Increased
26
Reduced
33
Closed
32

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$60.8M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$55.6M
3
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$40.9M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$39.9M
5
DYAX
DYAX CORPORATION
DYAX
+$35.8M

Top Sells

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$446M
2
ABBV icon
AbbVie
ABBV
+$89.8M
3
ADVM
Adverum Biotechnologies
ADVM
+$85.8M
4
BLUE
bluebird bio
BLUE
+$47.9M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$27.7M

Sector Composition

Rank Sector Weight
1 Healthcare 70.77%
2 Financials 3.42%
3 Technology 0.52%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$426M 14.19%
12,259,875
-532,814
-4% -$16.3M
AVDL
2
DELISTED
Avadel Pharmaceuticals
AVDL
$86.3M 2.88%
4,072,809
– –
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
$82.5M 2.75%
5,773,050
+700,000
+14% +$11.9M
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
$68.7M 2.29%
9,529,361
-2,305,234
-19% -$17M
DYAX
5
DELISTED
DYAX CORPORATION
DYAX
$65.8M 2.19%
2,483,507
+1,352,093
+120% +$35.8M
VNDA icon
6
Vanda Pharmaceuticals
VNDA
$327M
$60.7M 2.02%
4,784,157
+650,000
+16% +$7.01M
VTRS icon
7
Viatris
VTRS
$20.1B
$59.1M 1.97%
871,000
+861,000
+8,610% +$60.8M
GSK icon
8
GSK
GSK
$104B
$57.3M 1.91%
1,101,378
+402,830
+58% +$22.7M
ALPN
9
DELISTED
Alpine Immune Sciences Inc
ALPN
$56.5M 1.88%
+933,103
New +$55.6M
BLUE
10
DELISTED
bluebird bio
BLUE
$55M 1.83%
25,228
-23,509
-48% -$47.9M
WBA
11
DELISTED
Walgreens Boots Alliance
WBA
$54.8M 1.82%
648,501
+135,701
+26% +$11.7M
DVA icon
12
DaVita
DVA
$15.2B
$50.5M 1.68%
636,000
-94,000
-13% -$7.72M
AET
13
DELISTED
Aetna Inc
AET
$47.1M 1.57%
369,739
+85,439
+30% +$9.75M
UAM
14
DELISTED
Universal American Corp
UAM
$44.6M 1.49%
4,409,703
-776,445
-15% -$8.09M
GWPH
15
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$44.5M 1.48%
361,953
-1,747
-0.5% -$198K
CRL icon
16
Charles River Laboratories
CRL
$10.8B
$43M 1.43%
611,436
+321,986
+111% +$23.8M
EHTH icon
17
eHealth
EHTH
$47.3M
$41.4M 1.38%
3,264,588
– –
AERI
18
DELISTED
Aerie Pharmaceuticals
AERI
$39M 1.3%
2,211,644
+1,605,526
+265% +$29.4M
ATRS
19
DELISTED
Antares Pharma, Inc.
ATRS
$38.3M 1.27%
18,389,789
+6,311,471
+52% +$15.3M
TEVA icon
20
Teva Pharmaceuticals
TEVA
$37.3B
$38.2M 1.27%
+646,000
New +$39.9M
ONCE
21
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$38M 1.27%
631,192
– –
ELGX
22
DELISTED
Endologix Inc
ELGX
$37.6M 1.25%
244,990
+10,055
+4% +$1.66M
LRMR icon
23
Larimar Therapeutics
LRMR
$384M
$34.9M 1.16%
83,968
-3,547
-4% -$1.48M
ADPT
24
DELISTED
Adeptus Health Inc
ADPT
$34.6M 1.15%
364,000
+165,400
+83% +$11.4M
LKFT
25
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$33.1M 1.1%
+642,608
New +$34.1M
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2015 Portfolio in Review

As of Q2 2015, Deerfield Management held 152 positions worth $3B, down 2.8% from $3.09B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Deerfield Management withdrew a net $518M in Q2 2015, closing 32 positions and reducing 33 holdings. Its most notable exit was AUSPEX PHARMACEUTICALS INC COM STK (DE), an estimated $446M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 60% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Alpine Immune Sciences Inc worth $56.5M.

  • Deerfield Management's largest Q2 2015 buy was Alpine Immune Sciences Inc: 933,103 shares worth $56.5M.
  • Deerfield Management added most to Viatris in Q2 2015, an estimated $60.8M increase.
  • Deerfield Management's biggest Q2 2015 reduction was bluebird bio, cutting an estimated $47.9M.
  • Deerfield Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $446M.
  • Deerfield Management's ten largest holdings make up 36% of its $3B portfolio in Q2 2015.
  • Deerfield Management opened 30 new positions and closed 32 in Q2 2015.
  • Deerfield Management's portfolio value fell 2.8% quarter-over-quarter to $3B.

Based on Deerfield Management's 13F filing for Q2 2015, filed 14 Aug 2015.